HCWB (HCW Biologics) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HCWB HCW Biologics Inc HCWB
37 GF Score
Price $3.24
GF Value $43.71
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is HCW Biologics Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

HCWB
37GF Score
HCW Biologics Inc HCWB
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HCW Biologics (HCWB) Overvalued in 2026?

Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued. The current stock price of $3.24 is trading 92.6% below its estimated GF Value™ of $43.71. GuruFocus considers HCW Biologics to be Possible Value Trap.

Key valuation signals for HCWB:

  • Dividend-Payout-to-FFO:
  • GF Value™: $43.71 vs. price of $3.24 (92.6% below fair value)
  • GF Score™: 37/100 with 7 warning signs

No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HCW Biologics Business Description

Address 2929 N. Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
37GF Score

Get the complete analysis for HCWB

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.24
Price
$43.71
GF Value